Use of amiodarone in the therapy of primary ventricular arrhythmias in children

A. S. Pickoff, S. Singh, C. J. Flinn, G. S. Wolff, H. Gelband

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

4 children, ages 11-14 years, were diagnosed as having primary ventricular arrhythmias (3 ventricular tachycardia, 1 multifocal premature ventricular contractions) without underlying heart disease. All 4 patients were treated initially with standard antiarrhythmic drugs (quinidine, propranolol, procainamide) and either did not respond (3 patients) or experienced drug toxicity (quinidine - 1 patient) necessitating withdrawal of antiarrhythmic therapy. Amiodarone, a new antiarrhythmic agent, was initiated in a single oral daily dose of 10 mg/kg/day. All patients have shown a significant clinical response to oral amiodarone with either complete suppression of ventricular tachycardia in 2 patients, near complete suppression in 1 and abolition of multifocal premature ventricular contractions in the fourth patient. 2 patients have had corneal microdeposits detected by slitlamp examination and are receiving methylcellulose eye drops; no other adverse reactions have been encountered during the follow-up of 6 months to 3 years.

Original languageEnglish
Pages (from-to)73-82
Number of pages10
JournalDevelopmental Pharmacology and Therapeutics
Volume6
Issue number2
StatePublished - Jun 10 1983
Externally publishedYes

Fingerprint

Amiodarone
Cardiac Arrhythmias
Quinidine
Ventricular Premature Complexes
Ventricular Tachycardia
Therapeutics
Procainamide
Methylcellulose
Ophthalmic Solutions
Anti-Arrhythmia Agents
Drug-Related Side Effects and Adverse Reactions
Propranolol
Heart Diseases

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pickoff, A. S., Singh, S., Flinn, C. J., Wolff, G. S., & Gelband, H. (1983). Use of amiodarone in the therapy of primary ventricular arrhythmias in children. Developmental Pharmacology and Therapeutics, 6(2), 73-82.

Use of amiodarone in the therapy of primary ventricular arrhythmias in children. / Pickoff, A. S.; Singh, S.; Flinn, C. J.; Wolff, G. S.; Gelband, H.

In: Developmental Pharmacology and Therapeutics, Vol. 6, No. 2, 10.06.1983, p. 73-82.

Research output: Contribution to journalArticle

Pickoff, AS, Singh, S, Flinn, CJ, Wolff, GS & Gelband, H 1983, 'Use of amiodarone in the therapy of primary ventricular arrhythmias in children', Developmental Pharmacology and Therapeutics, vol. 6, no. 2, pp. 73-82.
Pickoff, A. S. ; Singh, S. ; Flinn, C. J. ; Wolff, G. S. ; Gelband, H. / Use of amiodarone in the therapy of primary ventricular arrhythmias in children. In: Developmental Pharmacology and Therapeutics. 1983 ; Vol. 6, No. 2. pp. 73-82.
@article{e99b2fd584e34c3aa6ec9c603cca0a52,
title = "Use of amiodarone in the therapy of primary ventricular arrhythmias in children",
abstract = "4 children, ages 11-14 years, were diagnosed as having primary ventricular arrhythmias (3 ventricular tachycardia, 1 multifocal premature ventricular contractions) without underlying heart disease. All 4 patients were treated initially with standard antiarrhythmic drugs (quinidine, propranolol, procainamide) and either did not respond (3 patients) or experienced drug toxicity (quinidine - 1 patient) necessitating withdrawal of antiarrhythmic therapy. Amiodarone, a new antiarrhythmic agent, was initiated in a single oral daily dose of 10 mg/kg/day. All patients have shown a significant clinical response to oral amiodarone with either complete suppression of ventricular tachycardia in 2 patients, near complete suppression in 1 and abolition of multifocal premature ventricular contractions in the fourth patient. 2 patients have had corneal microdeposits detected by slitlamp examination and are receiving methylcellulose eye drops; no other adverse reactions have been encountered during the follow-up of 6 months to 3 years.",
author = "Pickoff, {A. S.} and S. Singh and Flinn, {C. J.} and Wolff, {G. S.} and H. Gelband",
year = "1983",
month = "6",
day = "10",
language = "English",
volume = "6",
pages = "73--82",
journal = "Developmental Pharmacology and Therapeutics",
issn = "0379-8305",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Use of amiodarone in the therapy of primary ventricular arrhythmias in children

AU - Pickoff, A. S.

AU - Singh, S.

AU - Flinn, C. J.

AU - Wolff, G. S.

AU - Gelband, H.

PY - 1983/6/10

Y1 - 1983/6/10

N2 - 4 children, ages 11-14 years, were diagnosed as having primary ventricular arrhythmias (3 ventricular tachycardia, 1 multifocal premature ventricular contractions) without underlying heart disease. All 4 patients were treated initially with standard antiarrhythmic drugs (quinidine, propranolol, procainamide) and either did not respond (3 patients) or experienced drug toxicity (quinidine - 1 patient) necessitating withdrawal of antiarrhythmic therapy. Amiodarone, a new antiarrhythmic agent, was initiated in a single oral daily dose of 10 mg/kg/day. All patients have shown a significant clinical response to oral amiodarone with either complete suppression of ventricular tachycardia in 2 patients, near complete suppression in 1 and abolition of multifocal premature ventricular contractions in the fourth patient. 2 patients have had corneal microdeposits detected by slitlamp examination and are receiving methylcellulose eye drops; no other adverse reactions have been encountered during the follow-up of 6 months to 3 years.

AB - 4 children, ages 11-14 years, were diagnosed as having primary ventricular arrhythmias (3 ventricular tachycardia, 1 multifocal premature ventricular contractions) without underlying heart disease. All 4 patients were treated initially with standard antiarrhythmic drugs (quinidine, propranolol, procainamide) and either did not respond (3 patients) or experienced drug toxicity (quinidine - 1 patient) necessitating withdrawal of antiarrhythmic therapy. Amiodarone, a new antiarrhythmic agent, was initiated in a single oral daily dose of 10 mg/kg/day. All patients have shown a significant clinical response to oral amiodarone with either complete suppression of ventricular tachycardia in 2 patients, near complete suppression in 1 and abolition of multifocal premature ventricular contractions in the fourth patient. 2 patients have had corneal microdeposits detected by slitlamp examination and are receiving methylcellulose eye drops; no other adverse reactions have been encountered during the follow-up of 6 months to 3 years.

UR - http://www.scopus.com/inward/record.url?scp=0020570628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020570628&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 73

EP - 82

JO - Developmental Pharmacology and Therapeutics

JF - Developmental Pharmacology and Therapeutics

SN - 0379-8305

IS - 2

ER -